NSG 5240 Advanced Pharmacology Final Practice
Exam – 100 Verified Q&A with Rationales (/2026)
South College | School of Nursing
Course: NSG 5240 Advanced Pharmacology
Exam Type: Final Practice Exam
Academic Year:2026 | Updated: April 2026
Format: 100 Multiple-Choice Questions | Passing Score: 80% (80/100)
Includes: Verified Correct Answers + Clinical Rationales
All questions and answers are sourced from verified 2025/2026 NSG 5240 testing materials .
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–20)
1. A patient with liver cirrhosis has reduced metabolism of a drug that normally undergoes
extensive first-pass effect. How will this affect the oral dose of the drug?
- A) Increase the oral dose
- B) Switch to an intravenous formulation
- C) Maintain the same oral dose
- D) Administer with a high-fat meal
Correct Answer: B – Switch to an intravenous formulation
Rationale: Liver cirrhosis impairs portal circulation and hepatic function. Drugs with high
first-pass metabolism are extensively metabolized in the liver before reaching systemic
circulation. Switching to IV bypasses the hepatic portal system, delivering the drug directly into
systemic circulation and avoiding unpredictable metabolism and risk of toxicity .
2. A drug has a half-life of 12 hours. Approximately how many hours will it take to reach steady
state?
- A) 24 hours
- B) 36 hours
- C) 48 hours
- D) 60 hours
Correct Answer: D – 60 hours
Rationale: Steady state is achieved after approximately 4-5 half-lives of regular dosing. At this
point, drug accumulation and elimination are equal. For a 12-hour half-life: 5 × 12 hours = 60
hours. For example, a drug with a 24-hour half-life takes about 4-5 days to reach steady state .
,3. Which route of administration completely bypasses the first-pass effect?
- A) Oral
- B) Sublingual
- C) Rectal
- D) Intravenous
Correct Answer: D – Intravenous
Rationale: IV administration bypasses absorption barriers entirely, delivering 100% of the dose
into systemic circulation and completely avoiding portal circulation and hepatic first-pass
metabolism. Sublingual and rectal routes partially bypass first-pass effect but not completely .
4. The therapeutic index (TI) of a drug is 2. What does this indicate?
- A) The drug is extremely safe
- B) The toxic dose is twice the effective dose
- C) The effective dose is twice the toxic dose
- D) Monitoring is unnecessary
Correct Answer: B – The toxic dose is twice the effective dose
Rationale: TI = TD50/ED50 (toxic dose in 50% / effective dose in 50%). A TI of 2 means the
dose causing toxicity in 50% of patients is only twice the effective dose for 50% of patients. This
is a narrow therapeutic window (low safety margin), requiring therapeutic drug monitoring (e.g.,
warfarin, lithium, phenytoin) .
5. A drug with zero-order kinetics is characterized by:
- A) Constant percentage eliminated per unit time
- B) Exponential decline in plasma concentration
- C) Constant amount of drug eliminated per unit time
- D) Increased clearance with higher doses
Correct Answer: C – Constant amount of drug eliminated per unit time
Rationale: Zero-order kinetics (e.g., phenytoin, ethanol, high-dose aspirin) occurs when
metabolic enzymes are saturated. A constant amount (e.g., 10 mg/hour) is eliminated
regardless of concentration, leading to non-linear pharmacokinetics and disproportionate toxicity
with dose increases .
6. What is the effect of a competitive antagonist on the dose-response curve of an agonist?
- A) Reduced maximal response
- B) Rightward shift of the curve (higher EC50)
- C) Leftward shift of the curve
- D) No change
,Correct Answer: B – Rightward shift of the curve (higher EC50)
Rationale: A competitive antagonist binds reversibly to the same receptor as the agonist. It
increases the dose needed for the same effect, shifting the curve rightward; however, maximal
response remains achievable with enough agonist concentration .
7. A patient with chronic kidney disease has reduced GFR. Which drug property most likely
requires dose adjustment?
- A) High lipid solubility
- B) Extensive hepatic metabolism
- C) High renal excretion (unchanged drug)
- D) High protein binding
Correct Answer: C – High renal excretion (unchanged drug)
Rationale: Drugs primarily excreted unchanged by the kidneys (e.g., aminoglycosides, digoxin,
lithium) accumulate in renal impairment and require dose adjustment based on GFR to prevent
toxicity .
8. Which cytochrome P450 enzyme is most commonly involved in drug-drug interactions?
- A) CYP1A2
- B) CYP2D6
- C) CYP3A4
- D) CYP2C9
Correct Answer: C – CYP3A4
Rationale: CYP3A4 metabolizes over 50% of all drugs on the market and is inhibited or induced
by many commonly used agents (e.g., grapefruit juice inhibits it; rifampin induces it;
ketoconazole, erythromycin also inhibit it). This makes it the most frequent site of clinically
significant drug-drug interactions .
9. Which statement about prodrugs is correct?
- A) They are active upon administration
- B) They require biotransformation to become active
- C) They always have longer half-lives
- D) They cannot be given orally
Correct Answer: B – They require biotransformation to become active
Rationale: Prodrugs (e.g., enalapril, levodopa, codeine, clopidogrel) are pharmacologically
inactive as administered and require biotransformation (usually in the liver) to become the active
therapeutic compound. This can improve bioavailability or target specific tissues .
, 10. Enterohepatic recirculation tends to:
- A) Shorten drug half-life
- B) Prolong drug action and half-life
- C) Decrease bioavailability
- D) Increase first-pass metabolism
Correct Answer: B – Prolong drug action and half-life
Rationale: In enterohepatic recirculation, drug excreted in bile is reabsorbed in the intestines,
returning to the liver and systemic circulation. This recycling process prolongs the drug's
presence in the body and extends its half-life and duration of action .
11. Which transporter is responsible for hepatic uptake of many statins and is associated with
myopathy risk when inhibited?
- A) P-glycoprotein (P-gp)
- B) Organic anion transporting polypeptide OATP1B1
- C) Breast cancer resistance protein (BCRP)
- D) Multidrug resistance-associated protein 2 (MRP2)
Correct Answer: B – OATP1B1
Rationale: OATP1B1 transports statins from portal blood into hepatocytes for metabolism.
Genetic polymorphisms (e.g., SLCO1B1 gene) or inhibitors (e.g., cyclosporine, gemfibrozil)
reduce hepatic uptake, increasing systemic statin exposure and risk of
myopathy/rhabdomyolysis .
12. A drug is 95% protein bound. Which condition would most likely increase its free fraction
and risk of toxicity?
- A) Decreased liver blood flow
- B) Increased albumin due to dehydration
- C) Hypoalbuminemia (e.g., malnutrition, liver disease)
- D) Increased GFR
Correct Answer: C – Hypoalbuminemia
Rationale: Low albumin levels reduce protein binding sites, increasing the free (unbound) drug
fraction. Only free drug is pharmacologically active. This can lead to toxicity for highly
protein-bound drugs with narrow therapeutic indices (e.g., phenytoin, warfarin) even if total drug
levels appear normal .
13. A drug has a volume of distribution (Vd) of 500 L. This suggests:
- A) Drug is confined to plasma
- B) Drug is highly bound to plasma proteins
Exam – 100 Verified Q&A with Rationales (/2026)
South College | School of Nursing
Course: NSG 5240 Advanced Pharmacology
Exam Type: Final Practice Exam
Academic Year:2026 | Updated: April 2026
Format: 100 Multiple-Choice Questions | Passing Score: 80% (80/100)
Includes: Verified Correct Answers + Clinical Rationales
All questions and answers are sourced from verified 2025/2026 NSG 5240 testing materials .
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–20)
1. A patient with liver cirrhosis has reduced metabolism of a drug that normally undergoes
extensive first-pass effect. How will this affect the oral dose of the drug?
- A) Increase the oral dose
- B) Switch to an intravenous formulation
- C) Maintain the same oral dose
- D) Administer with a high-fat meal
Correct Answer: B – Switch to an intravenous formulation
Rationale: Liver cirrhosis impairs portal circulation and hepatic function. Drugs with high
first-pass metabolism are extensively metabolized in the liver before reaching systemic
circulation. Switching to IV bypasses the hepatic portal system, delivering the drug directly into
systemic circulation and avoiding unpredictable metabolism and risk of toxicity .
2. A drug has a half-life of 12 hours. Approximately how many hours will it take to reach steady
state?
- A) 24 hours
- B) 36 hours
- C) 48 hours
- D) 60 hours
Correct Answer: D – 60 hours
Rationale: Steady state is achieved after approximately 4-5 half-lives of regular dosing. At this
point, drug accumulation and elimination are equal. For a 12-hour half-life: 5 × 12 hours = 60
hours. For example, a drug with a 24-hour half-life takes about 4-5 days to reach steady state .
,3. Which route of administration completely bypasses the first-pass effect?
- A) Oral
- B) Sublingual
- C) Rectal
- D) Intravenous
Correct Answer: D – Intravenous
Rationale: IV administration bypasses absorption barriers entirely, delivering 100% of the dose
into systemic circulation and completely avoiding portal circulation and hepatic first-pass
metabolism. Sublingual and rectal routes partially bypass first-pass effect but not completely .
4. The therapeutic index (TI) of a drug is 2. What does this indicate?
- A) The drug is extremely safe
- B) The toxic dose is twice the effective dose
- C) The effective dose is twice the toxic dose
- D) Monitoring is unnecessary
Correct Answer: B – The toxic dose is twice the effective dose
Rationale: TI = TD50/ED50 (toxic dose in 50% / effective dose in 50%). A TI of 2 means the
dose causing toxicity in 50% of patients is only twice the effective dose for 50% of patients. This
is a narrow therapeutic window (low safety margin), requiring therapeutic drug monitoring (e.g.,
warfarin, lithium, phenytoin) .
5. A drug with zero-order kinetics is characterized by:
- A) Constant percentage eliminated per unit time
- B) Exponential decline in plasma concentration
- C) Constant amount of drug eliminated per unit time
- D) Increased clearance with higher doses
Correct Answer: C – Constant amount of drug eliminated per unit time
Rationale: Zero-order kinetics (e.g., phenytoin, ethanol, high-dose aspirin) occurs when
metabolic enzymes are saturated. A constant amount (e.g., 10 mg/hour) is eliminated
regardless of concentration, leading to non-linear pharmacokinetics and disproportionate toxicity
with dose increases .
6. What is the effect of a competitive antagonist on the dose-response curve of an agonist?
- A) Reduced maximal response
- B) Rightward shift of the curve (higher EC50)
- C) Leftward shift of the curve
- D) No change
,Correct Answer: B – Rightward shift of the curve (higher EC50)
Rationale: A competitive antagonist binds reversibly to the same receptor as the agonist. It
increases the dose needed for the same effect, shifting the curve rightward; however, maximal
response remains achievable with enough agonist concentration .
7. A patient with chronic kidney disease has reduced GFR. Which drug property most likely
requires dose adjustment?
- A) High lipid solubility
- B) Extensive hepatic metabolism
- C) High renal excretion (unchanged drug)
- D) High protein binding
Correct Answer: C – High renal excretion (unchanged drug)
Rationale: Drugs primarily excreted unchanged by the kidneys (e.g., aminoglycosides, digoxin,
lithium) accumulate in renal impairment and require dose adjustment based on GFR to prevent
toxicity .
8. Which cytochrome P450 enzyme is most commonly involved in drug-drug interactions?
- A) CYP1A2
- B) CYP2D6
- C) CYP3A4
- D) CYP2C9
Correct Answer: C – CYP3A4
Rationale: CYP3A4 metabolizes over 50% of all drugs on the market and is inhibited or induced
by many commonly used agents (e.g., grapefruit juice inhibits it; rifampin induces it;
ketoconazole, erythromycin also inhibit it). This makes it the most frequent site of clinically
significant drug-drug interactions .
9. Which statement about prodrugs is correct?
- A) They are active upon administration
- B) They require biotransformation to become active
- C) They always have longer half-lives
- D) They cannot be given orally
Correct Answer: B – They require biotransformation to become active
Rationale: Prodrugs (e.g., enalapril, levodopa, codeine, clopidogrel) are pharmacologically
inactive as administered and require biotransformation (usually in the liver) to become the active
therapeutic compound. This can improve bioavailability or target specific tissues .
, 10. Enterohepatic recirculation tends to:
- A) Shorten drug half-life
- B) Prolong drug action and half-life
- C) Decrease bioavailability
- D) Increase first-pass metabolism
Correct Answer: B – Prolong drug action and half-life
Rationale: In enterohepatic recirculation, drug excreted in bile is reabsorbed in the intestines,
returning to the liver and systemic circulation. This recycling process prolongs the drug's
presence in the body and extends its half-life and duration of action .
11. Which transporter is responsible for hepatic uptake of many statins and is associated with
myopathy risk when inhibited?
- A) P-glycoprotein (P-gp)
- B) Organic anion transporting polypeptide OATP1B1
- C) Breast cancer resistance protein (BCRP)
- D) Multidrug resistance-associated protein 2 (MRP2)
Correct Answer: B – OATP1B1
Rationale: OATP1B1 transports statins from portal blood into hepatocytes for metabolism.
Genetic polymorphisms (e.g., SLCO1B1 gene) or inhibitors (e.g., cyclosporine, gemfibrozil)
reduce hepatic uptake, increasing systemic statin exposure and risk of
myopathy/rhabdomyolysis .
12. A drug is 95% protein bound. Which condition would most likely increase its free fraction
and risk of toxicity?
- A) Decreased liver blood flow
- B) Increased albumin due to dehydration
- C) Hypoalbuminemia (e.g., malnutrition, liver disease)
- D) Increased GFR
Correct Answer: C – Hypoalbuminemia
Rationale: Low albumin levels reduce protein binding sites, increasing the free (unbound) drug
fraction. Only free drug is pharmacologically active. This can lead to toxicity for highly
protein-bound drugs with narrow therapeutic indices (e.g., phenytoin, warfarin) even if total drug
levels appear normal .
13. A drug has a volume of distribution (Vd) of 500 L. This suggests:
- A) Drug is confined to plasma
- B) Drug is highly bound to plasma proteins
